Business Wire1mon
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union
This follows its approval for the treatment of adults with prurigo nodularis by the United States ... with speed of itch relief therefore also prioritized by both patients and physicians.
AFP1mon
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union
Prurigo nodularis is a serious skin condition characterized ... with significant itch relief observed as early as Week 1. 24 The phase III OLYMPIA 1 and 2 trials evaluated the efficacy and safety ...